This was my latest column for the Free Lance-Star on Sunday June 27th. The FDA’s approval of a new drug to treat Alzheimer’s Disease has prompted a lot of hope. But also prompted three members of the FDA’s advisory committee to resign. Will the New Medicine Stop This? Aducanumab, marketed by Biogen and Eisai by…
Read more
